Jhawar SR, et al. - Researchers assessed if the use of combined modality therapy (CMT) in pediatric Hodgkin lymphoma (HL) is related with enhanced overall survival by conducting an observational cohort study. They used data from the National Cancer Database for evaluating clinical features and survival rates among 5,657 pediatric subjects (aged 0.1-21 years) who were diagnosed with stage I or II HL in the US. CMT and chemotherapy use was linked with the younger age group. Five-year survival post-treatment with CMT was improved by 2.8% vs chemotherapy alone in pediatric patients with early-stage HL. Perhaps over-reliance on clinical trials, which are designed to avoid consolidation radiotherapy is the reason for a nationwide decline in CMT use. The largest data set to date examining the role of CMT in pediatric HL is reflected in this study.